论文部分内容阅读
作者报道应用胎肝输注(FLI)作为急性粒系白血病(AML)强力诱导和维持化疗时的一种支持、辅助治疗,目的在于确定胎肝细胞(FLC)能否促进AML 缓解和延长生存期以及能否植入成人骨髓。1982年4月至1984年11月收治的27例初发 AML患者,年龄14—56岁,分成两组:对照组15例,静注柔红霉素(DNR)45mg/m~2/d 第1、2、3天,加阿糖胞苷(Ara-C)100mg/m~2/d 连用7天以诱导缓解并周期性巩固维持,支持治疗包括抗生素和必要时成份输血。FLI 组12例,除上述治疗外,在诱导化疗后不同时间和缓解期每个维持化疗程后,疗输注胎龄为10—24周(中数16周)、细胞数在0.07—34.0×10~8之间
The authors report the use of fetal liver infusion (FLI) as a supportive and adjuvant therapy for the strong induction and maintenance of chemotherapy in acute myeloid leukemia (AML) in order to determine whether fetal liver cells (FLCs) can promote AML remission and prolong survival. And whether adult bone marrow can be implanted. From April 1982 to November 1984, 27 patients with newly diagnosed AML, aged 14-56 years, were divided into two groups: 15 in the control group and 45 mg/m~2/d intravenously daunorubicin (DNR). On days 1, 2, and 3, Ara-C 100 mg/m~2/d was used for 7 days for induction of remission and periodic consolidation. Supportive therapy included antibiotics and blood transfusions as necessary. Twelve patients in the FLI group, in addition to the above-mentioned treatments, after each chemotherapy regimen at different times and remissions after induction chemotherapy, the infusion gestational age was 10 to 24 weeks (median 16 weeks), and the number of cells was 0.07 to 34.0 × Between 10~8